366 related articles for article (PubMed ID: 19442803)
1. [Bortezomib-induced acute neutrophilic dermatosis].
Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
3. Bortezomib-induced histiocytoid Sweet syndrome.
Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced Sweet's syndrome.
Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
[TBL] [Abstract][Full Text] [Related]
5. Sweet-like syndrome induced by bortezomib.
Kolb-Mäurer A; Kneitz H; Goebeler M
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
[No Abstract] [Full Text] [Related]
6. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
8. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
Kim JS; Roh HS; Lee JW; Lee MW; Yu HJ
Int J Dermatol; 2012 Dec; 51(12):1491-3. PubMed ID: 22998496
[No Abstract] [Full Text] [Related]
9. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
10. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
11. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Rosiñol L; Montoto S; Cibeira MT; Bladé J
Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
[TBL] [Abstract][Full Text] [Related]
15. Skin lesions induced by bortezomib.
Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
17. Bortezomib (velcade) for multiple myeloma.
Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
[No Abstract] [Full Text] [Related]
18. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Pitini V; Arrigo C; Altavilla G; Naro C
Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
[No Abstract] [Full Text] [Related]
19. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
Zobniw CM; Saad SA; Kostoff D; Barthel BG
Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
